Group 1 - The company has entered into a licensing agreement with FBD Biologics Limited, granting an exclusive license to develop, produce, commercialize, or otherwise utilize HCB101 and its derivative pharmaceutical products in specific fields and regions [1] - The licensing agreement is effective from the date of signing and will last until the expiration of the licensing product's patent rights, which is determined by the later of the following dates: (a) fifteen years from the first commercial sale of the licensed product; (b) the expiration date of the last valid claim of the patent covering the licensed product; and (c) the expiration of the market exclusivity period for the licensed product [1]